Autotaxin emerges as a therapeutic target for idiopathic pulmonary fibrosis: limiting fibrosis by limiting lysophosphatidic acid synthesis

Am J Respir Cell Mol Biol. 2012 Nov;47(5):563-5. doi: 10.1165/rcmb.2012-0235ED.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Animals
  • Clinical Trials as Topic
  • Humans
  • Idiopathic Pulmonary Fibrosis / drug therapy
  • Idiopathic Pulmonary Fibrosis / enzymology*
  • Idiopathic Pulmonary Fibrosis / metabolism
  • Lysophospholipids / biosynthesis*
  • Lysophospholipids / metabolism
  • Molecular Targeted Therapy
  • Phosphodiesterase Inhibitors / pharmacology
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Phosphoric Diester Hydrolases / metabolism*
  • Signal Transduction

Substances

  • Lysophospholipids
  • Phosphodiesterase Inhibitors
  • Phosphoric Diester Hydrolases
  • alkylglycerophosphoethanolamine phosphodiesterase
  • lysophosphatidic acid